• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Bacterial Vaginosis - Pipeline Review, H1 2012 Product Image

Bacterial Vaginosis - Pipeline Review, H1 2012

  • ID: 2167146
  • June 2012
  • 45 pages
  • Global Markets Direct

Bacterial Vaginosis – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Bacterial Vaginosis - Pipeline Review, H1 2012', provides an overview of the Bacterial Vaginosis therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Vaginosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Vaginosis. 'Bacterial Vaginosis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bacterial Vaginosis.
- A review of the Bacterial Vaginosis products under development by companies and universities/research READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bacterial Vaginosis Overview
Therapeutics Development
An Overview of Pipeline Products for Bacterial Vaginosis
Bacterial Vaginosis Therapeutics under Development by Companies
Bacterial Vaginosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Bacterial Vaginosis Therapeutics – Products under Development by Companies
Bacterial Vaginosis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Bacterial Vaginosis Therapeutics Development
Merck & Co., Inc.
Cytokine PharmaSciences, Inc.
Columbia Laboratories Inc.
Starpharma Holdings Limited
Bacterial Vaginosis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Metronidazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VivaGel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Boric Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metronidazole + Miconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketoconazole + Clindamycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COL-2401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-Vad - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bacterial Vaginosis Therapeutics – Drug Profile Updates
Bacterial Vaginosis Therapeutics – Discontinued Products
Bacterial Vaginosis Therapeutics - Dormant Products
Bacterial Vaginosis – Product Development Milestones
Featured News & Press Releases
Jan 11, 2012: Starpharma Receives FDA Special Protocol Assessment For Phase III Trials Of VivaGel For Treatment Of Bacterial Vaginosis
Nov 21, 2011: Starpharma Secures European Agreement On BV Phase III Treatment
Oct 10, 2011: Starpharma Secures FDA Agreement On Phase III VivaGel Bacterial Vaginosis Treatment Program
Aug 15, 2011: Starpharma Commences Bacterial Vaginosis Prevention Study Of VivaGel
May 23, 2011: Starpharma's VivaGel Demonstrates Efficacy In Bacterial Vaginosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Bacterial Vaginosis, H1 2012
Products under Development for Bacterial Vaginosis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Merck & Co., Inc., H1 2012
Cytokine PharmaSciences, Inc., H1 2012
Columbia Laboratories Inc., H1 2012
Starpharma Holdings Limited, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Bacterial Vaginosis Therapeutics – Drug Profile Updates
Bacterial Vaginosis Therapeutics – Discontinued Products
Bacterial Vaginosis Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Bacterial Vaginosis, H1 2012
Products under Development for Bacterial Vaginosis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos